Self-screen

About:

Self-screen focuses on cervical cancer screening and prevention.

Top Investors: EASME - EU Executive Agency for SMEs

Description:

The history of Self-screen is a track record in translational science. The company was founded in 2008 to advance the implementation of scientific discoveries in the field of cancer screening into routine practice. Our dedication is towards the development and clinical application of molecular assays for the early detection of cancer, thereby to the benefit of patients around the world. Currently, the company’s main focus is on cervical cancer screening and prevention. The company has two clinically validated assays on the market. We strive towards all-molecular screening to ensure objectivity, reproducibility and high-throughput possibilities. Our research and development pipeline currently focuses on the extension of our science towards other sample types, like urine, and towards other cancer types.

Total Funding Amount:

3.26M EUR

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Amsterdam, Noord-Holland, The Netherlands

Founded Date:

2008-01-01

Contact Email:

info(AT)self-screen.nl

Founders:

Chris Meijer, Daniëlle Heideman, Peter Snijders, Renske Steenbergen

Number of Employees:

1-10

Last Funding Date:

2015-07-01

IPO Status:

Private

Industries: